Clinical Trial

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

Study acronym: BEXMAB
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML); Phase 1 aims to identify the recommended phase 2 dose (RP2D) of bexmarilimab based on safety, tolerability and pharmacological activity; Phase 2 will investigate the preliminary efficacy of the combination treatment in selected indications from Phase 1.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-04 -> 2027-03 2026-04-24
minor Completion pushed: 2026-04 -> 2027-03 2026-04-24
Trial Details
NCT Number NCT05428969
Lead Sponsor Faron Pharmaceuticals Ltd
Conditions Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML
Enrollment 181 participants
Start Date 2022-06-02
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-04-23